CAR T Cancer Therapy: How It Treats Blood Cancers

CAR T cancer therapy is a highly specialized form of immunotherapy used to treat some blood cancers, especially when the disease has returned or not responded to standard treatment. It uses a patient’s own immune cells, modified in a laboratory, to recognize and attack cancer cells more effectively.

Overview of CAR T Cancer Therapy

CAR T cancer therapy, also called CAR T-cell therapy, is a type of immunotherapy that helps the immune system recognize and attack certain cancer cells. “CAR” stands for chimeric antigen receptor, which is a special receptor added to a patient’s T cells in the laboratory. T cells are part of the immune system and normally help the body fight infections and abnormal cells.

In this treatment, doctors collect T cells from the patient’s blood and send them to a specialized lab. There, the cells are genetically modified so they can better identify a specific target on cancer cells. The updated cells are then multiplied and returned to the patient through an infusion, where they can begin searching for and attacking cancer cells.

CAR T cancer therapy is most often used for blood cancers rather than solid tumors. It has changed treatment options for some people with advanced or hard-to-treat disease, especially when previous treatments have not worked well enough. Because it is complex and can cause significant side effects, it is usually performed in expert centers with multidisciplinary teams.

Which Blood Cancers Can It Treat?

CAR T cancer therapy is approved and used for selected blood cancers, depending on the exact diagnosis, a patient’s age, prior treatments, and the specific CAR T product available. It is not a single treatment for every cancer. Instead, it is tailored to particular disease types that carry certain targets on the surface of cancer cells.

Doctors may consider CAR T-cell therapy for some forms of leukemia, lymphoma, and multiple myeloma. In many cases, it is offered when the cancer has relapsed after treatment or has been refractory, meaning it did not respond adequately to standard therapies. Examples include certain B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and some cases of multiple myeloma.

Whether CAR T is appropriate depends on many clinical details, including the biology of the cancer, overall health, organ function, infection risk, and how quickly treatment is needed. A hematology and oncology team may compare it with other options such as chemotherapy, targeted therapy, stem cell transplant, or additional immunotherapy.

• Some acute lymphoblastic leukemias
• Some non-Hodgkin lymphomas
• Certain relapsed or refractory large B-cell lymphomas
• Some cases of mantle cell lymphoma or follicular lymphoma
• Selected cases of multiple myeloma

How the Treatment Process Works

CAR T cancer therapy usually takes place in stages over several weeks. The first step is an evaluation to confirm that the patient is a good candidate. This may include blood tests, heart and lung checks, imaging, bone marrow assessment when needed, and a detailed review of previous cancer treatments. Doctors also discuss the likely benefits, possible risks, and the need for close follow-up.

The next step is leukapheresis, a procedure that collects T cells from the blood. These cells are sent to a laboratory, where they are engineered to express the CAR receptor and then grown into larger numbers. Because manufacturing takes time, some patients may receive temporary treatment, sometimes called bridging therapy, to help keep the cancer under control while waiting for the CAR T cells to be prepared.

Before the CAR T cells are infused, patients usually receive a short course of lymphodepleting chemotherapy. This lowers some existing immune cells and helps the modified T cells expand and work more effectively after infusion. The CAR T cells are then given through an intravenous infusion, similar to a blood product or medication infusion.

After infusion, close monitoring is essential. Some patients stay in the hospital, while others may be monitored in a specialized outpatient program, depending on the treatment protocol and the person’s condition. The care team watches for side effects, checks blood counts and organ function, and evaluates how the cancer is responding over time.

Benefits and Possible Side Effects

One of the main strengths of CAR T cancer therapy is that it is highly targeted and personalized. It uses the patient’s own immune cells and can produce meaningful responses in some people whose cancer has returned or resisted other treatments. For certain patients, it may offer another chance at disease control when standard therapies are no longer enough.

At the same time, CAR T therapy can cause serious side effects and requires careful medical supervision. One important reaction is cytokine release syndrome, which happens when the activated immune system releases large amounts of inflammatory signals. Symptoms can range from fever and fatigue to low blood pressure, breathing difficulty, or more severe illness. Another recognized complication is neurologic toxicity, which may cause confusion, sleepiness, tremor, difficulty speaking, or seizures in some cases.

Other possible side effects include low blood counts, infection risk, low antibody levels, nausea, weakness, and effects related to previous chemotherapy. Not every patient experiences severe problems, and many side effects can be managed effectively when recognized early. This is why treatment is given in centers trained to detect and respond quickly to complications.

Patients and families are usually asked to stay near the treatment center for a period after infusion. They may also need a caregiver to help monitor symptoms and support daily needs. Following the care team’s instructions closely is an important part of safe recovery.

Who May Be Eligible for CAR T-Cell Therapy?

Eligibility for CAR T cancer therapy depends on both the cancer and the patient’s overall condition. Doctors consider the exact diagnosis, disease stage, prior treatments, pace of the illness, and whether the cancer cells carry the target that the CAR T product is designed to recognize. They also review general health, kidney and liver function, heart and lung status, and any active infections.

Some people may not be suitable candidates if they are too unwell for the process, have uncontrolled infection, or need treatment more urgently than the cell manufacturing timeline allows. In other cases, CAR T may still be possible after stabilizing symptoms or using another treatment first. The decision is individualized and often discussed by a multidisciplinary tumor board or blood cancer team.

Patients may also ask how CAR T compares with stem cell transplant. These are different therapies, though both can be used in advanced blood cancers. Depending on the disease type and treatment history, a specialist may discuss whether CAR T is an alternative to transplant, a bridge to transplant, or part of a broader treatment plan that may also involve leukemia care, lymphoma treatment, or management of multiple myeloma.

Diagnosis, Preparation, and Follow-Up Care

Before CAR T treatment begins, accurate diagnosis and staging are essential. Blood cancers are not all the same, and treatment planning depends on the exact subtype. Patients may need blood tests, bone marrow studies, imaging scans, and molecular or genetic testing to confirm the nature of the disease and guide the treatment approach.

Preparation also includes infection screening, medication review, vaccination planning where appropriate, and practical arrangements for the treatment period. Patients are often advised to report fever or new symptoms quickly, avoid infection exposures when possible, and keep all follow-up appointments. Because treatment may affect blood counts and immunity, supportive care is an important part of the overall plan.

After infusion, follow-up focuses on both safety and effectiveness. The care team monitors for side effects, checks how blood counts recover, and looks for signs that the cancer is responding. Some people may need transfusions, infection prevention measures, or immune globulin support if antibody levels remain low.

Long-term follow-up is also important because recovery can continue over weeks to months. The oncology team helps patients understand what symptoms are expected, when normal activities may gradually resume, and how future cancer surveillance will be handled. When appropriate, broader cancer treatment planning and immunotherapy support may be part of ongoing care.

Questions to Ask and When to Seek Medical Help

Patients considering CAR T cancer therapy often benefit from bringing a list of questions to their appointment. Helpful topics include why this treatment is being recommended, what alternatives exist, how long the process may take, what side effects are most important to watch for, and what kind of support will be needed at home. Understanding the plan in advance can make the experience feel more manageable.

After infusion, patients should follow the instructions given by their treatment center and seek urgent medical attention if they develop fever, confusion, shortness of breath, fainting, severe weakness, trouble speaking, seizures, chest pain, or any sudden worsening symptoms. Even symptoms that seem mild can be important after CAR T therapy, so prompt communication is encouraged.

It is also reasonable to ask about the expertise of the treating center, because this therapy requires coordination among hematologists, oncologists, intensive care specialists, neurologists, pharmacists, laboratory teams, and nurses. In experienced centers, treatment planning may also include bone marrow transplantation consultation when needed. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat blood cancers for international patients, including advanced therapies where appropriate.

Frequently asked questions

Is CAR T cancer therapy a type of chemotherapy?

No. CAR T cancer therapy is a form of immunotherapy that uses specially modified immune cells to target cancer. However, many patients do receive a short course of chemotherapy before infusion to help the CAR T cells work better.

What cancers is CAR T therapy mainly used for?

It is mainly used for selected blood cancers, including some leukemias, lymphomas, and multiple myeloma. It is most often considered when the cancer has come back or has not responded to standard treatment.

How long does the CAR T-cell therapy process take?

The full process often takes several weeks, starting with evaluation and T-cell collection. The laboratory manufacturing phase takes time, and close monitoring is needed after infusion, so treatment is more than a single-day event.

What are the main risks of CAR T cancer therapy?

Important risks include cytokine release syndrome, neurologic side effects, low blood counts, and infections. These complications can be serious, which is why treatment is given in specialized centers with experienced teams and careful follow-up.

Can CAR T therapy cure blood cancer?

For some patients, CAR T therapy can lead to deep and long-lasting remission. However, outcomes vary, and it is not possible to guarantee a cure. A specialist can explain what is realistic for a specific diagnosis and treatment history.

Will a patient need to stay in the hospital?

Some patients are admitted to the hospital, while others may be monitored in a specialized outpatient setting. The decision depends on the treatment protocol, overall health, and how the patient is doing after the infusion.

References

• National Cancer Institute
• American Cancer Society
• U.S. Food and Drug Administration
• Leukemia & Lymphoma Society
• European Society for Medical Oncology

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.